Fetal and Neonatal Neurobehavior and Prenatal Antidepressant Exposure

描述（由申请人提供）：每年至少有600，000名在美国出生的婴儿在妊娠期间暴露于母体重度抑郁症（MDD）。胎儿暴露于母体MDD与新生儿医学和神经行为缺陷以及儿童的长期情绪，行为和社会问题有关。MDD的治疗至关重要。目前，选择性5-羟色胺再摄取抑制剂（SSRI）和双重作用5-羟色胺和去甲肾上腺素再摄取抑制剂（SNRI）是MDD的一线药物治疗选择（统称SRI）。最近的研究表明，妊娠期暴露于SRI与短暂的不良新生儿症状有关，与成人中观察到的5-羟色胺毒性或停药综合征（戒断）一致。我们提出的研究将解决这一领域至关重要但未知的问题-如果症状与5-羟色胺毒性有关，暴露于母体MDD，或者如果它们构成真正的戒断综合征。这项拟议的研究汇集了一个由经验丰富的研究人员组成的跨学科团队，使用药物暴露模型来解决产前暴露对婴儿健康和发育影响的关键问题。我们的研究将使用一种受控的药物暴露方法，该方法已成功应用于其他合法和非法药物。我们计划研究四组，每组70名妇女，根据她们在孕晚期的治疗选择：1）SRI使用/没有当前MDD标准，2）MDD/没有药物治疗，3）MDD和SRI和4）没有当前MDD或SRI使用。精神病诊断将使用标准化临床访谈确定。我们将在孕28周和36周通过超声观察和胎心率监测来检查胎儿的神经行为。将在第0、1、2、4、7、14和30天使用系列神经行为评估和新生儿药物戒断评估量表检查新生儿，测量睡眠以及生理和行为反应性。我们将讨论3个主要的具体目标：1。确定妊娠期SRI暴露对胎儿和婴儿神经行为的影响，包括新生儿期的戒断。检查胎龄26 - 44周的神经行为发育概况，以及3.确定SRI暴露量、5-羟色胺代谢物水平和婴儿SRI血清药物水平是否与胎儿和婴儿神经行为（包括新生儿期戒断）相关，拟议的研究汇集了一个经验丰富的多学科团队，使用药物暴露模型来解决产前5-羟色胺再摄取抑制剂（SRI）暴露对婴儿健康和发育影响的关键问题。该模型将系统地评估归因于产前SRI暴露的神经行为影响的发展，将这些影响与母亲重度抑郁症暴露相关的影响区分开来。这项研究的数据将有助于制定更好的产前使用SRI药物的治疗指南，以及显示不良症状的婴儿的治疗指南。

DESCRIPTION (provided by applicant): Each year at least 600,000 infants born in the United States are exposed to maternal Major Depressive Disorder (MDD) during gestation. Fetal exposure to maternal MDD is associated with newborn medical and neurobehavioral deficits and long term emotional, behavioral, and social problems in the child. Treatment of MDD is critical. Currently, selective serotonin reuptake inhibitors (SSRIs) and dual-action serotonin and norepinephrine reuptake inhibitors (SNRIs) are the first-line pharmacological treatment choice for MDD (collectively SRIs). Recent studies suggest that gestational exposure to SRIs is associated with transient adverse neonatal symptoms consistent with serotonin toxicity or discontinuation syndrome (withdrawal) as seen in adults. Our proposed study will address critically important but unknown issues in this area - if the symptoms are related to serotonin toxicity, exposure to maternal MDD, or if they constitute a true withdrawal syndrome. The proposed study brings together an interdisciplinary team of experienced researchers to address critical questions on the effects of prenatal exposure on infant health and development using a drug exposure model. Our study will use a controlled, drug-exposure methodology that has been successfully applied to other licit and illicit drugs. We plan to study four groups of 70 women each based on their treatment choices by the third trimester: 1) SRI use/no current MDD criteria, 2) MDD/no medication treatment, 3) MDD and SRIs and 4) no current MDD or SRI use. Psychiatric diagnoses will be determined using a standardized clinical interview. We will examine fetal neurobehavior at 28 and 36 weeks gestation using ultrasound observation and fetal heart rate monitoring. Newborns will be examined utilizing serial neurobehavioral assessments and a neonatal drug withdrawal assessment scale on days 0, 1, 2, 4, 7, 14, and 30 with measures of sleep, and physiological and behavioral reactivity. We will adress 3 main specific aims: 1. Determine the effects of gestational SRI exposure on fetal and infant neurobehavior including withdrawal in the neonatal period, 2. Examine the neurobehavioral developmental profile from 26 to 44 weeks gestational age, and 3. Determine if amount of SRI exposure, serotonin metabolite levels, and infant SRI serum drug levels are related to fetal and infant neurobehavior including withdrawal in the neonatal period.The proposed study brings together an experienced multidisciplinary team to address critical questions on the effects of prenatal Serotonin Reuptake Inhibitors (SRI) exposure on infant health and development using a drug exposure model. The model will systematically evaluate the development of neurobehavioral effects attributed to prenatal SRI exposure, distinguishing these effects from those related to maternal major depression exposure. The data from this study will lead to the development of better treatment guidelines for the prenatal use of SRI medications as well as treatment guidelines for infants demonstrating adverse symptoms.